Skip to main content
. 2003 Nov;69(11):6620–6627. doi: 10.1128/AEM.69.11.6620-6627.2003

FIG. 5.

FIG. 5.

Immunogenicity of Blg41-60::Nuc fusion protein. Control strain NZ9000(pVE3655) (L−), control strain plus 20 μg of purified Blg41-60::Nuc [L− + (Blg41-60::Nuc)], 20 μg of purified Blg41-60::Nuc emulsified in CFA [CFA + (Blg41-60::Nuc)], or recombinant strain NZ9000(pSEC:Blg41-60::Nuc) (L+) was administrated subcutaneously to mice on days 1 and 21. Serum samples were taken on day 32. Specific IgG1 (A) and IgG2a (B) levels were quantified as described in Materials and Methods. Values for each mouse were determined in duplicate (•; five mice per group), and group means are shown. Statistical analyses were performed by one-way analysis of variance and Tukey's multiple comparison test. P values on the graph are precise.